17 completed. 17 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Mesenchymal Stromal Cells, Supportive Care - Sars-CoV2, Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 28 | 2021-02-12 | 2026-10-21 |
| Methylene Blue Treatment of COVID-19 Methylene Blue, Control Test - SARS-CoV2 | Phase 2 | Completed | Fondazione Epatocentro Ticino | 29 | 2020-11-05 | 2025-08-17 |
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) LSALT peptide, Placebo - COVID, Severe Acute Respiratory Syndrome | Phase 2 | Completed | Arch Biopartners Inc. | 61 | 2020-10-14 | 2025-07-09 |
| Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease N-acetylcysteine - COVID, Sars-CoV2 | Phase 2 | Completed | Cambridge Health Alliance | 165 | 2020-09-23 | 2021-05-28 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID-19, Sars-CoV2 | Phase 2 | Completed | Virginia Commonwealth University | 2 | 2020-09-02 | 2021-08-11 |
| Rhu-pGSN for Severe Covid-19 Pneumonia Recombinant human plasma gelsolin (Rhu-pGSN), Placebo - Sars-CoV2 | Phase 2 | Completed | BioAegis Therapeutics Inc. | 64 | 2020-07-30 | 2023-11-28 |
| Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2 | Phase 2 / Phase 3 | Completed | University Hospital, Bordeaux | 412 | 2020-07-29 | 2026-05-12 |
| Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 Favipiravir, Placebo, Standard of care treatment - Sars-CoV2, COVID-19 | Phase 2 | Completed | Stanford University | 149 | 2020-07-12 | 2022-07-13 |
| A Study of Quintuple Therapy to Treat COVID-19 Infection Hydroxychloroquine, Azithromycin, Vitamin C - COVID-19, Corona Virus Infection | Phase 2 | Completed | ProgenaBiome | 118 | 2020-06-22 | 2024-02-29 |
| A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Hydroxychloroquine, Vitamin C, Vitamin D - COVID-19, Coronavirus Infection | Phase 2 | Completed | ProgenaBiome | 254 | 2020-06-22 | 2026-11-04 |
| Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients COVID-19 Convalescent Plasma (CCP), Placebo - COVID-19, Sars-CoV2 | Phase 2 | Completed | Priscilla Hsue, MD | 34 | 2020-06-09 | 2022-10-07 |
| Using GM-CSF as a Host Directed Therapeutic Against COVID-19 Sargramostim, Normal Saline 0.9% - COVID, Sars-CoV2 | Phase 2 | Completed | Singapore General Hospital | 2 | 2020-06-02 | 2022-05-10 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 Peginterferon Lambda-1A, placebo - Sars-CoV2, Covid-19 | Phase 2 | Completed | University Health Network, Toronto | 157 | 2020-05-13 | 2023-12-13 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Viusid and Asbrip - Covid-19, Sars-CoV2 | Phase 2 | Completed | Catalysis SL | 60 | 2020-05-04 | 2021-01-08 |
| Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS - Sars-CoV2 | Phase 1 / Phase 2 | Completed | Andalusian Network for Design and Translation of Advanced Therapies | 26 | 2020-04-27 | 2022-04-06 |
COVID-19 (13) · Coronavirus Infections (5) · Respiratory Distress Syndrome (4) · Pneumonia (3) · Severe Acute Respiratory Syndrome (2) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Cytokine Release Syndrome (1) · Diabetes Mellitus (1) · Heart Diseases (1) · Kidney Diseases (1) · Liver Diseases (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Lymphoma, Follicular (1)
Coronaviridae Infections (15) · Infections (15) · Nidovirales Infections (15) · RNA Virus Infections (15) · Virus Diseases (15) · Respiratory Tract Diseases (14) · Respiratory Tract Infections (14) · Lung Diseases (13) · Pneumonia, Viral (12) · Coronavirus Infections (10) · Pneumonia (10) · Respiration Disorders (4) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2)
Ascorbic Acid (2) · Hydroxychloroquine (2) · Vitamin D (2) · Zinc (2) · Acetylcysteine (1) · Azithromycin (1) · COVID-19 Serotherapy (1) · Colony-Stimulating Factors (1) · Gelsolin (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Methylene Blue (1) · Palliative Care (1) · Saline Solution (1) · Telmisartan (1) · Vitamins (1)
ProgenaBiome (2) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Apellis Pharmaceuticals, Inc. (1) · Arch Biopartners Inc. (1) · Baylor College of Medicine (1) · BioAegis Therapeutics Inc. (1) · Cambridge Health Alliance (1) · Catalysis SL (1) · Fondazione Epatocentro Ticino (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Priscilla Hsue, MD (1) · Singapore General Hospital (1) · Stanford University (1) · University Health Network, Toronto (1) · University Hospital, Bordeaux (1)
United States (9) · Brazil (2) · Canada (2) · Spain (2) · Belarus (1) · Ecuador (1) · France (1) · Romania (1) · Singapore (1) · Switzerland (1) · Turkey (Türkiye) (1)
Sabine Hazan, MD (2) · Andrei Y Hancharou, Dr. (1) · Annie Leutkemeyer, MD (1) · Antonio Abbate, MD, PhD (1) · Eduard A Dotsenko, Dr., prof. (1) · Helen Heslop, MD (1) · Jenny Low, MBBS (1) · Jordan Feld, MD (1) · LaQuisa Hill, MD (1) · Mark J DiNubile, MD (1) · Natalia G Antonevich, Dr. (1) · Priscilla Hsue, MD (1)
PMID 32555385, PMID 32788708, PMID 33050924, PMID 33556319, PMID 33624010, PMID 33754144, PMID 34473343, PMID 35446944, PMID 38454482, PMID 38490660